SCHEMBL22154802

SCHEMBL22154802

CC(C)(CC(N)Cc1ccc([N+](=O)[O-])c(OCc2ccccc2)c1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MYC P01106 2/20 0.45
MAX P61244 1/20 0.45
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CTSV O60911 2/20 0.41
CTSL P07711 2/20 0.41
CYP19A1 P11511 1/20 0.41
POLB P06746 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 2/20 0.40
ABCB1 P08183 1/20 0.39
PTGES O14684 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22154560 0.92 CTSV (0.48) ALDH1A1MEN1KMT2ACTSVCTSL
SCHEMBL28639840 0.92 CTSV (0.48) ALDH1A1MEN1KMT2ACTSVCTSL
SCHEMBL22120986 0.82 BCL2 (0.47) MYCMAXALDH1A1HTT
SCHEMBL1732723 0.80 ALDH1A1 (0.62) MYCMAXALDH1A1MEN1KMT2A
SCHEMBL6592912 0.78 MYC (0.48) MYCMAXALDH1A1MEN1KMT2A
SCHEMBL6592921 0.78 MYC (0.48) MYCMAXALDH1A1MEN1KMT2A
SCHEMBL29162420 0.77 ACE (0.54) CTSL
SCHEMBL3920761 0.77 MYC (0.50) MYCMAXALDH1A1MEN1KMT2A
SCHEMBL27607664 0.77 MYC (0.43) MYCMAXALDH1A1MEN1KMT2A
SCHEMBL6593577 0.76 MYC (0.52) MYCMAXALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12144864-B2 Tubulysins and protein-tubulysin conjugates REGENERON PHARMACEUTICALS, INC. (US) 2024-11-19 US disclosed
CN-118027137-A Tubulysin and protein-tubulysin conjugates 里珍纳龙药品有限公司 2024-05-14 CN disclosed
CN-113454097-A Tubulysins and protein-tubulysin conjugates 里珍纳龙药品有限公司 2021-09-28 CN disclosed
WO-2020132658-A2 TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES REGENERON PHARMACEUTICALS, INC. (US) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12144864-B2 Tubulysins and protein-tubulysin conjugates SDCBP, TEK, TEKT1 MYC 3572/4885MAX 2589/4885ALDH1A1 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.